Orca-T Demonstrates Favorable Quality of Life and Healthcare Resource Use Compared to Standard Allohsct Plus Tac/MTX for GVHD Prevention in a Randomized phase 3 Clinical Trial (Precision-T)

Transplantation and Cellular Therapy 2026

View at publisher

Authors: Arpita P. Gandhi, Anna Pavlova, James Scott McClellan, Ai Li, Bronwen E. Shaw, Rachel N. Cusatis, Rocio Manghani, Andrea Blank

DOI: 10.1016/j.jtct.2025.12.431

Cited by: 0

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation Renal Transplantation Outcomes and Treatments Immunodeficiency and Autoimmune Disorders